Stifel downgraded Orthofix from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | $14.00 | Hold | TD Cowen |
| 10/28/2025 | $22.00 | Buy | Stifel |
| 1/22/2025 | $24.00 | Buy | Canaccord Genuity |
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel |
The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligen
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Needham Virtual MedTech & Diagnostics 1x1 Conference - Virtual, August 10, 2026, 1x1 Meetings Canaccord Genuity’s 46th Annual Growth Conference - Boston, August 12, 2026, Fireside Chat Time: 9:30 am Eastern Time Interested parties can access the live and archived webcast of the Canaccord Genuity fireside chat in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the "Investors" section o
Company to Host Conference Call on Wednesday, August 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting o
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00
Stifel resumed coverage of Orthofix with a rating of Buy and set a new price target of $22.00
Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00
8-K - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
SD - Orthofix Medical Inc. (0000884624) (Filer)
The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case.ORLANDO, Fla. and LONDON, July 21, 2026 /PRNewswire/ -- eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligen
Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
Company to Host Conference Call on Wednesday, August 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 8700861. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting o
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, incre
Company to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Informati
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)